Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China, has announced the successful completion of a financing round, raising a total of USD 63.3 million. This includes a Series B funding round of USD 47.3 million and a credit facility of USD 16 million. The funds will be allocated to accelerate the development of its radiotherapeutics pipeline and enhance manufacturing capabilities, as well as to refine its proprietary discovery platform, UniRDC.
The Series B round was led by Aramco Ventures’ Prosperity7 Ventures and a leading life science fund, with participation from Xia Yan Medical USD Fund, Dart Xia Yan Fund, and Guanghua Wutong Fund, along with Sky9 Capital and existing investors Chengwei Capital, Sequoia China, and Junson Capital. The USD 16 million credit facility will support pipeline development and the construction of manufacturing facilities in Belgium.
Among its pipeline, Full-Life Tech is developing 225Ac-FL-020, a next-generation PSMA-targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapy has shown promising anti-tumor effects in pre-clinical models, highlighting the company’s commitment to advancing radiotherapeutic options for cancer patients.- Flcube.com
